151 related articles for article (PubMed ID: 26677977)
41. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
42. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
[TBL] [Abstract][Full Text] [Related]
43. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.
Deng YR; Ma HD; Tsuneyama K; Yang W; Wang YH; Lu FT; Liu CH; Liu P; He XS; Diehl AM; Gershwin ME; Lian ZX
J Autoimmun; 2013 Oct; 46():25-34. PubMed ID: 23948302
[TBL] [Abstract][Full Text] [Related]
44. Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management.
Ai L; Xu Z; Yang B; He Q; Luo P
Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1121-1127. PubMed ID: 31679411
[No Abstract] [Full Text] [Related]
45. Fluvastatin enhances sorafenib cytotoxicity in melanoma cells via modulation of AKT and JNK signaling pathways.
Zhang S; Doudican NA; Quay E; Orlow SJ
Anticancer Res; 2011 Oct; 31(10):3259-65. PubMed ID: 21965734
[TBL] [Abstract][Full Text] [Related]
46. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
McLellan B; Kerr H
Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
[TBL] [Abstract][Full Text] [Related]
47. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
[TBL] [Abstract][Full Text] [Related]
48. Identification of Keratinocyte Cytoprotectants against Toxicity by the Multikinase Inhibitor Sorafenib Using Drug Repositioning.
Kamata Y; Kato R; Tominaga M; Toyama S; Komiya E; Utsumi J; Kaneko T; Suga Y; Takamori K
JID Innov; 2024 May; 4(3):100271. PubMed ID: 38585194
[TBL] [Abstract][Full Text] [Related]
49. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
50. Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.
Ikeda M; Fujita T; Amoh Y; Mii S; Matsumoto K; Iwamura M
Urol Int; 2013; 91(4):482-3. PubMed ID: 23969404
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model.
Parvinian A; Casadaban LC; Hauck ZZ; van Breemen RB; Gaba RC
Diagn Interv Radiol; 2015; 21(3):235-40. PubMed ID: 25835078
[TBL] [Abstract][Full Text] [Related]
52. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
53. Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide.
Bins S; van Doorn L; Phelps MA; Gibson AA; Hu S; Li L; Vasilyeva A; Du G; Hamberg P; Eskens F; de Bruijn P; Sparreboom A; Mathijssen R; Baker SD
Clin Transl Sci; 2017 Jul; 10(4):271-279. PubMed ID: 28371445
[TBL] [Abstract][Full Text] [Related]
54. Clinical characteristics, treatment outcomes, and prognosis in patients with MKIs-associated hand-foot skin reaction: a retrospective study.
Shou L; Chen J; Shao T; Zhang Y; Zhao S; Chen S; Shu Q
Support Care Cancer; 2023 Jun; 31(7):375. PubMed ID: 37273007
[TBL] [Abstract][Full Text] [Related]
55. A Potential Association of Zinc Deficiency and Tyrosine Kinase Inhibitor-Induced Hand-Foot Skin Reaction.
Yeh CN; Huang WK; Lu CW; Chen CP; Lin SH; Pan YR; Wu CE
Biol Trace Elem Res; 2023 Dec; 201(12):5540-5545. PubMed ID: 36892689
[TBL] [Abstract][Full Text] [Related]
56. The Efficacy and Safety of the Shouzu Ning Decoction Treatment for Multi-Kinase Inhibitors-Associated Severe Hand-Foot Skin Reaction.
Shou L; Shao T; Zhao F; Chen S; Chen Q; Shu Q
Cancer Manag Res; 2021; 13():45-53. PubMed ID: 33442293
[TBL] [Abstract][Full Text] [Related]
57. Clinically relevant drug interactions with multikinase inhibitors: a review.
Hussaarts KGAM; Veerman GDM; Jansman FGA; van Gelder T; Mathijssen RHJ; van Leeuwen RWF
Ther Adv Med Oncol; 2019; 11():1758835918818347. PubMed ID: 30643582
[TBL] [Abstract][Full Text] [Related]
58. Hand-Foot Skin Reaction with Sunitinib: A Rare Case Report with Review of Literature.
Das S; Roy AK; Barman S; Roy A
Indian J Dermatol; 2020; 65(6):522-525. PubMed ID: 33487712
[TBL] [Abstract][Full Text] [Related]
59. Concurrent hand-foot skin reaction and hair depigmentation with sunitinib: report of a case and literature review of kinase inhibitors and blocking antibodies.
Bansal S; Sardana K; Singh K; Garg VK
Indian J Dermatol; 2014 Nov; 59(6):588-91. PubMed ID: 25484390
[TBL] [Abstract][Full Text] [Related]
60. Rigid Scaffolds Are Promising for Designing Macrocyclic Kinase Inhibitors.
Zhao Z; Bourne PE
ACS Pharmacol Transl Sci; 2023 Aug; 6(8):1182-1191. PubMed ID: 37588756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
